Alto Neuroscience Cash Flow Statement
NYSE: ANROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
24.37+0.34 (+1.41%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alto Neuroscience free cash flow
In fiscal 2025, Alto Neuroscience generated -$51.8 million of operating cash flow and spent $24,000 on capital expenditures. That left free cash flow of -$51.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Alto Neuroscience cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -63.24M | -61.43M | -36.30M |
| Net Income growth (YoY) | — | — | — |
| Depreciation & Amortization | 661.00K | 502.00K | 373.00K |
| Stock-Based Compensation | 8.11M | 7.63M | 2.89M |
| Change in Working Capital | 322.00K | 53.00K | -341.00K |
| Operating Cash Flow | -51.77M | -47.42M | -33.45M |
| Capital Expenditures | -24.00K | -2.08M | -470.00K |
| Investing Cash Flow | -24.00K | -2.08M | -470.00K |
| Debt Repaid | -10.21M | 0 | — |
| Financing Cash Flow | 60.08M | 135.69M | 68.13M |
| Net Change in Cash | 8.26M | 86.18M | 34.20M |
| Free Cash Flow | -51.79M | -49.50M | -33.92M |
This table shows 3 annual periods of Alto Neuroscience's cash flow statement, from FY 2025 back to FY 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ANRO's reporting calendar. What is a cash flow statement?